Role of the leukemia-associated transcription factor STAT3 in platelet physiology.

Abstract:

:Actinomycin D, a transcriptional inhibitor, was found to inhibit platelet potentiation by thrombopoietin (TPO), suggesting that TPO stimulation of platelets involves mitochondrial transcription. We sought to determine a possible role for leukemia-associated signal transducers and activators of transcription (STAT) proteins as mitochondrial transcription factors, focusing specifically on STAT3 in human platelets. We found TPO stimulation of platelets activated STAT3 in vitro, that STAT3 was present in platelet mitochondrial-rich fractions as determined by Western Blot analysis and was capable of binding to the regulatory D-loop region of human mitochondrial DNA upon activation. These results suggest that platelet signaling pathways activated by TPO may affect mitochondrial transcription via activation of STAT3.

journal_name

Leuk Lymphoma

journal_title

Leukemia & lymphoma

authors

Vassilev AO,Lorenz DR,Tibbles HE,Uckun FM

doi

10.1080/1042819022386716

keywords:

subject

Has Abstract

pub_date

2002-07-01 00:00:00

pages

1461-7

issue

7

eissn

1042-8194

issn

1029-2403

journal_volume

43

pub_type

杂志文章
  • Prevention and treatment of hepatic venocclusive disease after high-dose cytoreductive therapy.

    abstract::Venocclusive disease of the liver (VOD) is one of the most common and serious complications following stem cell transplantation. High-dose chemotherapy or chemoradiotherapy injures the structures of Zone 3 of the liver acinus and produces the clinical syndrome of hepatomegaly or right upper quadrant pain, jaundice, an...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199809059219

    authors: Richardson P,Bearman SI

    更新日期:1998-10-01 00:00:00

  • Cytogenetics of hybrid acute leukemias.

    abstract::Although the recognition of hybrid acute leukemia (HAL) is still controversial, several reports have described cytogenetic findings in these leukemias over the last 3 years. A distinct chromosomal profile appears to be associated with different immunologic subsets of HAL. The classical t(15;17), and inv(16) as well as...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199509075298

    authors: Cuneo A,Boogaerts M,Ferrant A,Michaux JL,Bosly A,Louwagie A,Van den Berghe H,Balsamo R,Roberti G,Bardi A

    更新日期:1995-01-01 00:00:00

  • The emerging role of immune checkpoint based approaches in AML and MDS.

    abstract::The development of immune checkpoint inhibitors represents a major breakthrough in the field of cancer therapeutics. Pursuant to their success in melanoma and numerous solid tumor malignancies, these agents are being investigated in hematological malignancies including acute myelogenous leukemia (AML) and myelodysplas...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428194.2017.1344905

    authors: Boddu P,Kantarjian H,Garcia-Manero G,Allison J,Sharma P,Daver N

    更新日期:2018-04-01 00:00:00

  • Analysis of HTLV-I in Hodgkin's Disease.

    abstract::Both Epstein-Barr virus (EBV) and the human T-cell leukemia virus I (HTLV-I) have been implicated in the generation of human lymphoproliferative disorders such as Burkitt's lymphoma, Hodgkin's disease (HD) and acute T-cell leukemia (ATL). In Hodgkin's disease EBV has been recently detected in Hodgkin's and Sternberg-R...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199109068088

    authors: Tesch H,Jücker M,Krönke M,Diehl V

    更新日期:1991-01-01 00:00:00

  • Predictive factors for central nervous system involvement in non-Hodgkin's lymphoma: significance of very high serum LDH concentrations.

    abstract::Factors predictive for central nervous system (CNS) involvement at presentation were investigated in 152 patients with non-Hodgkin's lymphoma (NHL) except for lymphoblastic cell lymphoma and small noncleaved cell lymphoma. Twelve patients developed CNS involvement during their disease course. The incidence was 7.9% of...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190009087024

    authors: Tomita N,Kodama F,Sakai R,Koharasawa H,Hattori M,Taguchi J,Fujita H,Tanabe J,Fujisawa S,Fukawa H,Harano H,Kanamori H,Miyashita H,Matsuzaki M,Ogawa K,Motomura S,Maruta A,Ishigatsubo Y

    更新日期:2000-07-01 00:00:00

  • Treatment of refractory acute leukemia with timed sequential chemotherapy using topotecan followed by etoposide + mitoxantrone (T-EM) and correlation with topoisomerase II levels.

    abstract::A phase I/II clinical study evaluated 17 patients with refractory/recurrent acute leukemia treated with 1.5 mg/m2/day topotecan on days 1-3 followed by etoposide (100 mg/m2/day)+mitoxantrone (10 mg/m2/day) on days 4, 5 and 9, 10. Timed sequential chemotherapy using the topoisomerase I-inhibitor topotecan before the to...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.1080/10428190290021339

    authors: Mainwaring MG,Rimsza LM,Chen SF,Gomez SP,Weeks FW,Reddy V,Lynch J,May WS,Kahn S,Moreb J,Leather H,Braylan R,Rowe TC,Fieniewicz KJ,Wingard JR

    更新日期:2002-05-01 00:00:00

  • Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice.

    abstract::Due to Cytochrome P450 3A (CYP3A) metabolism, clinical trials of ibrutinib-treated chronic lymphocytic leukemia (CLL) patients prohibited concurrent medications metabolized by CYP3A. We evaluated concomitant medication use in 118 ibrutinib-treated CLL patients outside the context of clinical trials. Seventy-five (64%)...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2016.1251592

    authors: Finnes HD,Chaffee KG,Call TG,Ding W,Kenderian SS,Bowen DA,Conte M,McCullough KB,Merten JA,Bartoo GT,Smith MD,Leis J,Chanan-Khan A,Schwager SM,Slager SL,Kay NE,Shanafelt TD,Parikh SA

    更新日期:2017-06-01 00:00:00

  • Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis.

    abstract::Nilotinib has shown favorable safety in patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic (CML-CP) or accelerated phase (CML-AP) who failed prior imatinib, and superior efficacy over imatinib in newly diagnosed Ph+ patients with CML-CP. Reported here are the efficacy and sa...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,多中心研究

    doi:10.3109/10428194.2011.627480

    authors: Nicolini FE,Masszi T,Shen Z,Gallagher NJ,Jootar S,Powell BL,Dorlhiac-Llacer PE,Zheng M,Szczudlo T,Turkina A

    更新日期:2012-05-01 00:00:00

  • Successful treatment for multiple cerebral hemorrhage in a newly diagnosed patient with acute promyelocytic leukemia.

    abstract::Acute promyelocytic leukemia (APL) is characterized by severe bleeding associated with coagulation abnormalities. High incidence of disseminated intravascular coagulation (DIC) in APL often causes early hemorrhagic death. We report a case of APL with massive cerebral hemorrhage and respiratory failure in a 24-year old...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/1042819031000067521

    authors: Chung CY,Hsu NC,Horng HC,Chang CS

    更新日期:2003-06-01 00:00:00

  • Interferon-gamma and human megakaryopoiesis.

    abstract::Interferon-gamma (IFN-gamma) exhibits various properties including antigrowth activity in neoplastic and normal cells and regulatory roles in immune responses and hematopoiesis, but studies of IFN-gamma effects on human megakaryopoiesis have been inconclusive. Recently we have used serum-free culture of purified CD34+...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199809057590

    authors: Tsuji K,Muraoka K,Nakahata T

    更新日期:1998-09-01 00:00:00

  • Increased frequency of homozygosity for HLA class II loci in female patients with chronic lymphocytic leukemia.

    abstract::The etiology of chronic lymphocytic leukemia (CLL) appears to be influenced by genetic factors which may contribute to its differential, gender- and age-specific incidence. The presented study is the first, which investigated the frequencies of DNA-typed alleles of all relevant human leukocyte antigens (HLA) loci in C...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190290021588

    authors: Mueller LP,Machulla HK

    更新日期:2002-05-01 00:00:00

  • The expression of anamorsin in diffuse large B cell lymphoma: possible prognostic biomarker for low IPI patients.

    abstract::Anamorsin is a cell-death-defying factor, which was originally isolated as a molecule that conferred resistance to apoptosis induced by growth factor starvation. In order to evaluate anamorsin expression levels in malignant lymphoma, we immunostained paraffin-embedded sections with anti-anamorsin monoclonal antibodies...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190701713697

    authors: Shizusawa T,Shibayama H,Murata S,Saitoh Y,Sugimoto Y,Matsumura I,Ogawa H,Sugiyama H,Fukuhara S,Hino M,Kanamaru A,Yamauchi A,Aozasa K,Kanakura Y

    更新日期:2008-01-01 00:00:00

  • Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea.

    abstract::Hydroxyurea (HU) has traditionally been the first-line treatment for patients with polycythemia vera (PV) or essential thrombocythemia (ET) at high risk for vascular complications. However, approximately 20-25% of patients develop resistance or intolerance to HU and must be treated with second-line therapies. Resistan...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428194.2014.893310

    authors: Sever M,Newberry KJ,Verstovsek S

    更新日期:2014-12-01 00:00:00

  • Molecular variant of hairy cell leukemia with poor prognosis.

    abstract::Hairy cell leukemia variant (HCLv), described 30 years ago, was reported to present with high disease burden and less often leukopenia, and later was reported to be resistant to purine analogs. Patients with HCLv were overrepresented among patients with HCL seeking relapsed/refractory trials. To compare clinical and m...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2011.565841

    authors: Arons E,Kreitman RJ

    更新日期:2011-06-01 00:00:00

  • Human NK cells in health and disease: clinical, functional, phenotypic and DNA genotypic characteristics.

    abstract::Natural killer (NK) cells are the subject of great current interest because of their possible (in vivo) role in tumour cell surveillance and killing, and because of the potential application of cytokine-modulated NK cells in cancer immunotherapy. In addition, clonal proliferations of NK-associated (NKa) cell populatio...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199209049794

    authors: Richards SJ,Scott CS

    更新日期:1992-08-01 00:00:00

  • Ex vivo cytokine expansion of peripheral blood Ph-negative cells in chronic myeloid leukaemia.

    abstract::Hematopoietic progenitors can be expanded ex vivo in the presence of various cytokine combinations. Since normal early progenitor or stem cells persist in the blood and bone marrow of patients with Philadelphia chromosome [Ph]-positive chronic myeloid leukaemia (CML), the selection of normal (Ph-negative) progenitor c...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199809059255

    authors: Mahon FX,Pigeonnier-Lagarde V,Chahine H,Maguer-Satta V,Ripoche J,Reiffers J

    更新日期:1998-12-01 00:00:00

  • The role of ATM mutations and 11q deletions in disease progression in chronic lymphocytic leukemia.

    abstract::Abstract ATM gene alteration is a frequent event in pathogenesis of chronic lymphocytic leukemia (CLL) and occurs as monoallelic loss in the form of 11q23 deletion, with and without mutation in the remaining ATM allele. ATM is a principal DNA damage response gene and biallelic ATM alterations lead to ATM functional lo...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428194.2013.829919

    authors: Stankovic T,Skowronska A

    更新日期:2014-06-01 00:00:00

  • Evaluation of the MDR1, ABCG2, Topoisomerases IIalpha and GSTpi gene expression in patients affected by aggressive mantle cell lymphoma treated by the R-Hyper-CVAD regimen.

    abstract::The genomic profile of mantle cell lymphoma (MCL) has been reported to be significantly different from that of other indolent lymphoproliferative disorders, Topoisomerase IIalpha, glutathione-s-transferasepi (GSTpi) and ABCG2 (BCRP) chemoresistance genes being over-expressed in MCL. In our study, expression levels of ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190701402895

    authors: Galimberti S,Nagy B,Benedetti E,Pacini S,Brizzi S,Caracciolo F,Papineschi F,Ciabatti E,Guerrini F,Fazzi R,Canestraro M,Petrini M

    更新日期:2007-08-01 00:00:00

  • Expression of CD203c on basophils as a marker of immunoglobulin E-mediated (L)-asparaginase allergy.

    abstract::Immediate allergy to l-asparaginase (ASP) is a major obstacle in treating lymphoid malignancies. ASP-specific immunoglobulin G (ASP-IgG) has been used as a surrogate marker. Recently, the CD203c-basophil activation test (BAT) was found to be useful in diagnosing IgE-mediated allergies. We compared the diagnostic utili...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2013.794944

    authors: Hino M,Shimojo N,Ochiai H,Inoue Y,Ando K,Chikaraishi K,Ota S,Okimoto Y,Sunami S,Nakamura R,Teshima R,Sato Y,Kohno Y

    更新日期:2014-01-01 00:00:00

  • Transplantation of unmanipulated allogeneic PBSC: preliminary report on 24 patients.

    abstract::To explore the feasibility and potential advantages of PBSC in allogeneic transplantation, we grafted 24 patients (age 16-57, median 37) with different hematologic diseases (ALL = 10, AML = 5, MM = 4, NHL = 2, CML = 1, MDS = 1, AA = 1), 23 HLA-identical to their siblings and 1 partially matched. Cells were collected f...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199709058600

    authors: Majolino I,Scime' R,Cavallaro AM,Santoro A,Catania P,Cannella S,Vasta S,Indovina A,Marceno' R

    更新日期:1997-12-01 00:00:00

  • Poor outcome of adult acute lymphoblastic leukemia patients carrying the (1;19)(q23;p13) translocation.

    abstract::The (1;19)(q23;p13) translocation, leading to the production of the E2A/PBX1 fusion transcript, is one of the most common translocations in pediatric B-lineage acute lymphoblastic leukemia (ALL). It was assumed to be associated with a poor clinical outcome, although intensive therapy and bone marrow transplantation ha...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190500331261

    authors: Piccaluga PP,Malagola M,Rondoni M,Ottaviani E,Testoni N,Laterza C,Visani G,Pileri SA,Martinelli G,Baccarani M

    更新日期:2006-03-01 00:00:00

  • Vasculitis and leukemia.

    abstract::Vasculitis may accompany neoplasias and be of paraneoplastic type or associated with drugs used in patient treatment. We evaluated skin biopsies of twenty-eight cases with vasculitis accompanying leukemias reviewed and clinical outcome was evaluated. Eleven of the 28 cases had paraneoplastic vasculitis and 17 had vasc...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190009054886

    authors: Paydaş S,Zorludemir S,Sahin B

    更新日期:2000-12-01 00:00:00

  • Clinical applicability of proposed algorithm for identifying individuals at risk for hereditary hematologic malignancies.

    abstract::Multiple genes have been identified to cause hereditary predispositions to hematologic malignancies, and characterized by an increased risk to develop myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and/or aplastic anemia (AA). Referral algorithms for patients who may be at higher risk have been propose...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2019.1630618

    authors: Clifford M,Bannon S,Bednar EM,Czerwinski J,Davis J,Dunnington L,Shahrukh Hashmi S,DiNardo CD

    更新日期:2019-12-01 00:00:00

  • IL-7 in allogeneic transplant: clinical promise and potential pitfalls.

    abstract::Much progress has been made in the field of allogeneic stem cell transplantation. However, one major barrier is the delay in immune recovery that can persist for months post-transplant and results in increased susceptibility to infection and relapse of malignancy. Strategies to improve immune recovery must be balanced...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190600555876

    authors: Snyder KM,Mackall CL,Fry TJ

    更新日期:2006-07-01 00:00:00

  • Level of CD 20-expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia.

    abstract::Rituximab (IDEC C2B8) is a chimeric human-mouse monoclonal anti-CD20 antibody that has been proven to be effective for the treatment of patients with CD20 positive leukemia and lymphoma. The level of CD20-expression in patients with B-cell chronic lymphocytic leukemia (B-CLL) is low in comparison to other B-cell lymph...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190210178

    authors: Perz J,Topaly J,Fruehauf S,Hensel M,Ho AD

    更新日期:2002-01-01 00:00:00

  • Retrovirus tests of human leukemia/lymphoma cell lines at DSM.

    abstract::Permanently established human cell lines can produce several retroviruses. It is important to routinely test such cell lines for human T cell lymphotropic virus (HTLV) type I and II, and for human immunodeficiency virus (HIV) type 1 and 2 in order to exclude any potential biohazard from cell lines producing human retr...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199309087007

    authors: Häne BG,Drexler HG

    更新日期:1993-10-01 00:00:00

  • Regulatory T-cells in B-cell chronic lymphocytic leukemia: their role in disease progression and autoimmune cytopenias.

    abstract::Regulatory T-cells (Tregs) have been shown to be important for the balance of autoimmunity and oncogenesis. Tregs have a protective role in autoimmune diseases and conversely promote oncogenesis. Chronic lymphocytic leukemia (CLL) is unique in being at the cross-roads of oncogenesis and autoimmunity. We studied Tregs,...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2012.728287

    authors: Lad DP,Varma S,Varma N,Sachdeva MU,Bose P,Malhotra P

    更新日期:2013-05-01 00:00:00

  • The role of FAS-mediated apoptosis in chronic myelogenous leukemia.

    abstract::Clinical observation and laboratory evidence suggest that immune mechanisms play an important role in the natural control of evolution of the Ph+ clone in chronic phase as well as during progression of chronic myelogenous leukemia (CML). The understanding of these mechanisms could facilitate development of innovative ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428190009089429

    authors: Selleri C,Maciejewski JP

    更新日期:2000-04-01 00:00:00

  • Decreased 5-hydroxymethylcytosine levels are associated with TET2 mutation and unfavorable overall survival in myelodysplastic syndromes.

    abstract::The clinical significance and mechanisms of TET2 are not well defined in myeloid malignancies. We detected TET2 mutations and assayed its catalyzing conversion product 5-hydroxymethylcytosine (5-hmC) in 61 Chinese patients with MDS. Ten patients were identified to have TET2 mutations (16.4%). 5-hmC levels in patients ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2013.778408

    authors: Liu X,Zhang G,Yi Y,Xiao L,Pei M,Liu S,Luo Y,Zhong H,Xu Y,Zheng W,Shen J

    更新日期:2013-11-01 00:00:00

  • Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype.

    abstract::The addition of arsenic trioxide (ATO) to frontline therapy of acute promyelocytic leukemia (APL) has been shown to result in significant improvements in disease-free survival (DFS). FLT3 mutations are frequently observed in APL, but its prognostic significance remains unclear. We analyzed 245 newly diagnosed adult pa...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.3109/10428194.2013.842985

    authors: Poiré X,Moser BK,Gallagher RE,Laumann K,Bloomfield CD,Powell BL,Koval G,Gulati K,Holowka N,Larson RA,Tallman MS,Appelbaum FR,Sher D,Willman C,Paietta E,Stock W

    更新日期:2014-07-01 00:00:00